| |
CHD HR (95%CI)
|
Hard CHD HR (95%CI)
|
|---|
|
E/N
|
Model 1
|
Model 2
|
E/N
|
Model 1
|
Model 2
|
|---|
|
FPG-WHO (mmol/L)
|
|
< 6.1
|
156/327
|
1.00
|
1.00
|
41/327
|
1.00
|
1.00
|
|
6.1–6.9
|
19/44
|
0.89 (0.55–1.43)
|
0.83 (0.51–1.35)
|
7/44
|
1.27 (0.57–2.84)
|
1.01 (0.44–2.32)
|
|
≥ 7
|
27/37
|
1.89 (1.25–2.87)
|
1.97 (1.28–3.03)
|
10/37
|
2.31 (1.15–4.62)
|
2.56 (1.21–5.39)
|
|
FPG-ADA (mmol/L)
|
|
< 5.6
|
120/253
|
1.00
|
1.00
|
30/253
|
1.00
|
1.00
|
|
5.6–6.9
|
55/118
|
1.04 (0.75–1.43)
|
1.02 (0.73–1.41)
|
18/118
|
1.39 (0.77–2.49)
|
1.30 (0.71–2.40)
|
|
≥ 7
|
27/37
|
1.94 (1.27–2.97)
|
2.03 (1.30–3.16)
|
10/37
|
2.50 (1.22–5.12)
|
2.84 (1.31–6.19)
|
|
2 h-PCPG (mmol/L)
|
|
< 7.8
|
112/240
|
1.00
|
1.00
|
31/240
|
1.00
|
1.00
|
|
7.8–11.0
|
51/105
|
1.02 (0.73–1.42)
|
1.00 (0.70–1.40)
|
13/105
|
0.97 (0.51–1.85)
|
0.93 (0.47–1.83)
|
|
≥ 11
|
39/63
|
1.46 (1.01–2.11)
|
1.46 (1.00–2.15)
|
14/63
|
1.91 (1.01–3.60)
|
1.95 (0.99–3.85)
|
- Model 1: age and sex
-
Model 2: model 1+ body mass index, current smoking, family history of premature CVD, hypertension, hypercholesterolemia, low HDL-C, heart rate, use of aspirin, use of beta blockers and low physical activity.
- E event in the target group, N total sample size in the target group, CVD cardiovascular disease, CHD coronary heart disease, HR hazard ratio, CI confidence interval, FPG fasting plasma glucose, 2h-PCPG 2h post challenge plasma glucose, WHO World Health Organization, ADA American Diabetes Association
